Osteopore (ASX:OSX), a pioneer in regenerative medicine, announced an exclusive distribution partnership with Medprin Biotech to penetrate the Latin American market.
The strategic collaboration leverages the strengths of Medprin, a subsidiary of the Shenzhen-listed Medprin Regenerative Medical Technologies, to bring Osteopore's bioresorbable solutions to a region spanning 20 countries, including major economies like Brazil, Argentina, and Mexico.
The partnership focuses specifically on the craniofacial reconstruction market, which remains Osteopore's most established and technologically advanced product segment.
By integrating Osteopore's 3D-printed biomimetic implants with Medprin’s robust neurosurgery-focused distribution network, the two companies aim to address critical needs in neurosurgery, orbital reconstruction, and maxillofacial trauma.
The Latin American medical device market represents a significant growth frontier for regenerative technologies.
With Medprin’s parent company boasting a market capitalisation of approximately 4.9 billion Malaysian ringgit, the alliance provides Osteopore with the financial and logistical backing necessary to scale rapidly.
"This agreement strengthens our distribution line-up and positions our bioresorbable technology at the forefront of surgical innovation in emerging markets," the company noted.
At the time of reporting, Osteopore's share price was $0.0090.